| Literature DB >> 25353386 |
Kęstutis Rutkauskas1, Asta Zubrienė2, Ingrida Tumosienė3, Kristina Kantminienė4, Marytė Kažemėkaitė5, Alexey Smirnov6, Justina Kazokaitė7, Vaida Morkūnaitė8, Edita Čapkauskaitė9, Elena Manakova10, Saulius Gražulis11, Zigmuntas J Beresnevičius12, Daumantas Matulis13.
Abstract
A series of N-aryl-β-alanine derivatives andEntities:
Mesh:
Substances:
Year: 2014 PMID: 25353386 PMCID: PMC6271771 DOI: 10.3390/molecules191117356
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthesis route of acid 4 and dihydropyrimidinedione 5 and the thio analogue 6.
Scheme 2Synthesis route of compounds 7–10.
Scheme 3Synthesis route of hydrazones 11–17 and compounds 18 and 19.
Scheme 4Synthesis route of triazoles 22 and 23 and oxadiazoles 24 and 25.
Compound dissociation constants for six human CA isoforms, determined by the fluorescent thermal shift assay and isothermal titration calorimetry (values in the brackets) at pH 7.0, 37 °C.
| CA I | CA II | CA VI | CA VII | CA XII | CA XIII | ||
|---|---|---|---|---|---|---|---|
| -NH2 | 100 | 13.0 | 56.0 | 50.0 | 67.0 | 100 | |
| 40 | 12.5 | 62.5 | 22.2 | 9.5 | 33.3 | ||
| >200 | 40 | >200 | >200 | >200 | >200 | ||
| 3.85 | 0.833 | 12.5 | 1.54 | 5.56 | 8.33 | ||
| 1.11 | 0.667 | 8.3 | 1.61 | 5.56 | 2.86 | ||
| 35.7 | 9.10 | 71.4 | 35.7 | 33.3 | 58.8 | ||
| 55.6 | 10.5 | 62.5 | 28.6 | 33.3 | 76.9 | ||
| 58.8 | 10.0 | 50.0 | 28.6 | 33.3 | 76.9 | ||
| 170 | 20.0 | 140 | 100 | 130 | 83.0 | ||
| 45.5 | 7.14 | 71.4 | 28.6 | 33.3 | 50.0 | ||
| 15.4 | 1.85 | 25.0 | 12.5 | 33.3 | 5.56 | ||
| 11.5 | 1.43 | 25.0 | 16.7 | 50.0 | 4.35 | ||
| 12.5 | 1.82 | 7.10 | 5.88 | 31.3 | 7.14 | ||
| 12.5 | 2.00 | 6.7 | 12.5 | 33.3 | 8.33 | ||
| 37.0 | 8.33 | 50.0 | 25.0 | 33.3 | 55.6 | ||
| 20.0 | 3.60 | 25.0 | 25.0 | 67.0 | 50.0 | ||
| 1.67 (0.750) | 0.667 (0.454) | 27.0 (ND) | 3.33 (0.90) | 14.3 (ND) | 4.00 (1.00) | ||
| 16.7 | 2.0 | 25.0 | 11.1 | 28.6 | 6.25 | ||
| 28.6 | 4.0 | 7.1 | 12.5 | 1.85 | 18.5 | ||
| 9.09 | 4.0 | 8.3 | 5.56 | 5.56 | 9.09 | ||
| ND | ND | ND | ND | ND | ND | ||
| 10.0 | 2.0 | 11.1 | 6.67 | 6.67 | 10.0 | ||
| 12.5 | 4.55 | 33.3 | 4.55 | 5.88 | 26.3 | ||
| 5.88 | 1.18 | 28.6 | 5.60 | 10.5 | 3.33 | ||
| 0.100 | 0.181 | 13.3 | 0.769 | 2.70 | 0.40 | ||
| 0.0133 | 0.0714 | 13.3 | 0.200 | 0.588 | 0.100 | ||
| 0.0333 | 0.133 | 13.3 | 0.454 | 1.81 | 0.167 | ||
| 0.0290 | 0.100 | 11.8 | 0.400 | 3.30 | 0.222 | ||
| 0.00667 | 0.0625 | 10.0 | 0.120 | 0.770 | 0.0667 | ||
| 0.0060 (0.022) | 0.0435 (0.040) | 14.3 (ND) | 0.125 (0.192) | 0.670 (0.22) | 0.0222 (0.078) | ||
| 0.0333 | 0.0667 | 3.20 | 0.286 | 2.00 | 1.40 | ||
| 0.500 | 0.278 | 8.30 | 1.00 | 6.25 | 2.86 | ||
| 0.200 b | 0.130 b | 4.0 | 0.170 b | 2.50 b | 1.40 b | ||
| BSA | 7.14 | 1.79 | 14.0 | 6.67 | 12.50 | 10.0 | |
| AZM c | 1.40 | 0.017 | 0.180 | 0.017 | 0.133 | 0.050 |
ND—not determined due to the limited solubility of the compound; a—entire compound structure, not the R group; b—compound synthesis and binding data described in [36]; c—data taken from [37].
Figure 1The fluorescent thermal shift assay (FTSA) data for compound 20 binding to CA XII (a) and 31 binding to CA I (b). Panels on the top (a,b) show the protein melting curves at several added compound concentrations. Panel on the bottom (c) shows the dependence of the protein melting temperatures T on ligand concentrations. Datapoints are from the experimental values from the upper panels and the curves in panel c are simulated according to the model [38].
Figure 2Calorimetric ITC titrations of CA II with 18 (a) and 31 (b). The experiments were performed at 37 °C in 50 mM phosphate buffer (pH 7.0), 100 mM NaCl and 2% DMSO.
Figure 3The view of the electron density of the compounds 31 (a) and 18 (b) located in the active center of CA II as determined by X-ray crystallography. The catalytic Zn(II) atoms are shown as blue spheres. The electron density difference maps are contoured at 2.5σ; (c) The superposition of 18 (green), 31 (yellow) and benzenesulfonamide (magenta) from the crystal structure PDB ID 2WEJ [39] bound in the active site of CA II show the identical orientation of the benzene ring. The active site residues of CA II are shown in grey while the histidine residues holding the zinc atom are transparent.
X-ray crystallographic data collection and refinement statistics. All datasets were collected at 100 K, test set size was 10%.
| Protein-Compound | CA II-31 | CA II-18 |
|---|---|---|
| PDB ID | 4Q6D | 4Q6E |
| Spacegroup | P21 | P21 |
| Unit cell, Å | a = 42.13, b = 41.20, c = 71.81 α = γ = 90°, β = 104.19° | a = 42.24, b = 41.24, c = 72.19 α = γ = 90°, β = 104.30° |
| Number of chains | 1 | 1 |
| Resolution, Å | 39.73–1.12 | 39.88–1.12 |
| Nref (unique) | 87368 | 85569 |
| Rmerge, (outer shell) | 0.076 (0.166) | 0.063 (0.193) |
| I/σ (outer shell) | 13.6 (7.0) | 14.4 (6.4) |
| Multiplicity (outer shell) | 6.5 (5.1) | 6.5 (5.2) |
| Completeness (%) (outer shell) | 95.8 (80.2) | 92.8 (66.7) |
| Number of atoms | 2583 | 2552 |
| Number of solvent molecules | 299 | 321 |
| 0.128 (0.154) | 0.130 (0.158) | |
| RMS bonds/angles | 0.025 (2.605) | 0.024 (2.362) |
| Average B-factors (Å2) | 16.370 | 14.630 |
| main chain: | 13.3 | 11.7 |
| side chains: | 17.4 | 15.3 |
| solvent: | 28.6 | 25.2 |
| inhibitor: | 17.4 | 19.0 |